Beneficial effect of cinacalcet in a child with familial hypocalciuric hypercalcemia

Pediatr Nephrol. 2010 Sep;25(9):1747-50. doi: 10.1007/s00467-010-1547-5. Epub 2010 May 22.

Abstract

We describe a child with familial hypocalciuric hypercalcemia (FHH) in whom the hypercalcemia seemed to interfere with tissue healing after tympanoplasty. Consequently, he was placed on cinacalcet (30 mg/day), changed after 2 weeks to 60 mg/day. The treatment resulted in a decrease in serum parathyroid hormone (PTH) from 148 to 32 pg/mL (normal 7-75) and ionized calcium from 1.48 to 1.23 mmol/L (1.13-1.34), as well as successful healing of the revised surgical scar. Over the 12-month treatment period no complications were noted. We conclude that cinacalcet may be considered a new, and currently the only, tool in treating children with symptomatic FHH.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biomarkers / blood
  • Biomarkers / urine
  • Calcium* / blood
  • Calcium* / urine
  • Child
  • Cinacalcet
  • Genetic Predisposition to Disease
  • Humans
  • Hypercalcemia / blood
  • Hypercalcemia / drug therapy*
  • Hypercalcemia / genetics
  • Hypercalcemia / urine
  • Male
  • Mutation
  • Naphthalenes / therapeutic use*
  • Parathyroid Hormone / blood
  • Pedigree
  • Receptors, Calcium-Sensing / genetics
  • Time Factors
  • Treatment Outcome
  • Tympanoplasty
  • Wound Healing / drug effects

Substances

  • Biomarkers
  • CASR protein, human
  • Naphthalenes
  • PTH protein, human
  • Parathyroid Hormone
  • Receptors, Calcium-Sensing
  • Calcium
  • Cinacalcet